Market Place
Sourcing Support
Japan Approves Incyte`s Minjuvi for R/R Follicular Lymphoma
22 Dec 2025 //
BUSINESSWIRE
Incyte Japan Approves Zynyz For First-Line Advanced Anal Cancer
22 Dec 2025 //
BUSINESSWIRE
Incyte Announces Change To Its Board Of Directors
12 Dec 2025 //
BUSINESSWIRE
Incyte` INCA033989, Receives FDA Breakthrough Therapy Designation
07 Dec 2025 //
BUSINESSWIRE
Incyte Presents INCA033989 Data in Myelofibrosis at ASH 2025
07 Dec 2025 //
BUSINESSWIRE
Vitiligo Foundation Applauds Incyte-Winnie Harlow Partnership
03 Dec 2025 //
BUSINESSWIRE
Incyte Taps Winnie Harlow To Model Vitiligo Awareness
02 Dec 2025 //
FIERCE PHARMA
Incyte Names Richard Hoffman As EVP & General Counsel
01 Dec 2025 //
PHARMIWEB
Incyte To Present At Upcoming Investor Conferences
19 Nov 2025 //
BUSINESSWIRE
Incyte Gets CHMP Nod For Minjuvi In Relapsed Follicular Lymphoma
17 Nov 2025 //
BUSINESSWIRE
Incyte Expands Moments Of Clarity Program For Vitiligo
06 Nov 2025 //
BUSINESS WIRE
Prelude Loses CMO, Pauses SMARCA2 Degraders, Scores Incyte Cash
04 Nov 2025 //
FIERCE BIOTECH
Incyte To Present Over 50 Abstracts at 2025 ASH Meeting
03 Nov 2025 //
BUSINESSWIRE
Incyte to Present at Upcoming Investor Conferences
30 Oct 2025 //
BUSINESSWIRE
Incyte & Enable Injections Announce Partnership for enFuse System
27 Oct 2025 //
BUSINESS WIRE
Incyte Unveils Ph 3b Opzelura Data In Moderate Atopic Dermatitis
25 Oct 2025 //
BUSINESSWIRE
Incyte Reveals Phase 1 Data On TGF?r2×Pd-1 Bispecific Antibody
19 Oct 2025 //
BUSINESSWIRE
Incyte To Present Tgf?r2×Pd-1 Antibody And KRAS G12D Inhibitor
14 Oct 2025 //
BUSINESSWIRE
Incyte To Report Third Quarter Financial Results
08 Oct 2025 //
BUSINESSWIRE
Incyte Issues Inducement Grant Under Nasdaq LR 5635(c)(4)
24 Sep 2025 //
BUSINESSWIRE
Incyte Appoints Dave Gardner as EVP and Chief Strategy Officer
22 Sep 2025 //
BUSINESSWIRE
Incyte Gets FDA OK for Opzelura in Kids with Atopic Dermatitis
18 Sep 2025 //
BUSINESSWIRE
FDA Approves Incyte`s Eczema Cream for Pediatric Patients
18 Sep 2025 //
REUTERS
Incyte to Showcase Dermatology Progress at EADV Congress 2025
10 Sep 2025 //
BUSINESSWIRE
Incyte Unveils HS TRUTHS on Hidradenitis Suppurativa Experience
03 Sep 2025 //
BUSINESSWIRE
Incyte sheds light on life with HS in new HCP campaign
03 Sep 2025 //
FIERCE PHARMA
Incyte Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
27 Aug 2025 //
BUSINESSWIRE
Incyte Taps Soni Basi as EVP and Chief Human Resources Officer
25 Aug 2025 //
CONTRACTPHARMA
Incyte to Present at Upcoming Investor Conferences
19 Aug 2025 //
BUSINESSWIRE
Actuate, Incyte, Pitt to Test Elraglusib in Pancreatic Cancer
06 Aug 2025 //
GLOBENEWSWIRE
Incyte`s CFO Christiana Stamoulis Steps Down
05 Aug 2025 //
BUSINESSWIRE
Incyte`s Q2 2025 Financial Results and Clinical Program Updates
29 Jul 2025 //
BUSINESSWIRE
Incyte to Present Bispecific and KRAS Data at ESMO 2025
24 Jul 2025 //
BUSINESSWIRE
Sun Pharma Settles Litigation with Incyte Corp Over Leqselvi
14 Jul 2025 //
ECONOMICTIMES
Incyte to Report Second Quarter Financial Results
10 Jul 2025 //
BUSINESSWIRE
Incyte Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
02 Jul 2025 //
BUSINESSWIRE
Incyte Appoints Bill Meury Chief Executive Officer
26 Jun 2025 //
CONTRACTPHARMA
Incyte Appoints Bill Meury CEO as Hoppenot Retires
26 Jun 2025 //
BUSINESSWIRE
FDA Reviewing Opzelura Cream for Kids With Dermatitis
20 Jun 2025 //
BUSINESSWIRE
Incyte Announces FDA Approval of Monjuvi for Lymphoma
19 Jun 2025 //
BUSINESSWIRE
Incyte presents positive data for mutCALR therapy at EHA2025
15 Jun 2025 //
BUSINESSWIRE
Qiagen, Incyte Team Up on MPN Companion Diagnostics
15 Jun 2025 //
BUSINESSWIRE
Incyte’s Retifanlimab Phase 3 Data in SCAC Published in Lancet
12 Jun 2025 //
BUSINESSWIRE
Specialised Therapeutics Expands Incyte Deal With 2 Therapies
12 Jun 2025 //
PR NEWSWIRE
Incyte Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
06 Jun 2025 //
BUSINESSWIRE
Incyte Announces Multiple Presentation, Late-Breaking Data at EHA
03 Jun 2025 //
BUSINESSWIRE
Incyte to Present at Upcoming Investor Conference
27 May 2025 //
BUSINESSWIRE
Incyte Secures Anal Cancer Nods Years After FDA Rejection
17 May 2025 //
FIERCE PHARMA
Incyte`s Biologics Zynyz Receives Suppl Approval in US
15 May 2025 //
FDA
Incyte Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
07 May 2025 //
BUSINESSWIRE
Incyte, Novartis reach settlement in Jakafi royalty dispute
06 May 2025 //
FIERCE PHARMA
Incyte to Present at Upcoming Investor Conference
01 May 2025 //
BUSINESSWIRE
Incyte predicts low tariff impact, blood cancer drug forecast
29 Apr 2025 //
REUTERS
Incyte Reports 2025 Q1 Financials and Clinical Program Updates
29 Apr 2025 //
BUSINESSWIRE
Incyte to Present Early-Stage Oncology Data at AACR 2025
25 Apr 2025 //
BUSINESSWIRE
Incyte to Present New Oncology Data at 2025 ASCO Annual Meeting
23 Apr 2025 //
BUSINESSWIRE
Sun Pharma beats Incyte in appeals, teeing up US alopecia launch
12 Apr 2025 //
FIERCE PHARMA
Incyte to Report First Quarter Financial Results
10 Apr 2025 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
07 Apr 2025 //
BUSINESSWIRE
Incyte reports positive results from Phase 3 trials of Povorcitinib
17 Mar 2025 //
BUSINESSWIRE
